ClinicalTrials.gg

Program

piclidenoson

Also written as “CF101”, “Piclidenoson” and “CF101 2mg”.

Its studies are mostly in Psoriasis · Arthritis, Rheumatoid · Keratoconjunctivitis Sicca · Glaucoma · COVID-19, led by Can-Fite BioPharma.

Furthest: phase 3, since Nov 3, 201015 company-led studies, 2 open or runningNext primary completion: Aug 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Can-Fite BioPharma152 open or runningphase 3since Nov 3, 2010Jan 23, 2006Aug 31, 2027phase 2 · NCT07410455

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 23, 2006First study: phase 2 study in Arthritis, RheumatoidFirst studyNCT00280917 · 254 enrolled · United States, Bulgaria, Israel and more
  2. Jul 6, 2006Phase 2 study in Keratoconjunctivitis SiccaNCT00349466 · 80 enrolled · Israel
  3. Jan 29, 2007Phase 2 study in PsoriasisNCT00428974 · 76 enrolled · Israel
  4. Nov 8, 2007Phase 2 study in Arthritis, RheumatoidNCT00556894 · 253 enrolled · Bulgaria, Czechia, Israel and more
  5. Feb 3, 2009Phase 2 study in Osteoarthritis, KneeNCT00837291 · Israel
  6. Dec 15, 20092 phase 2 studiesNCT01033422, NCT01034306
  7. Nov 3, 2010Phase 3 study in Keratoconjunctivitis SiccaNCT01235234 · 236 enrolled · Israel
  8. Dec 9, 2010Phase 3 study in PsoriasisNCT01265667 · 293 enrolled · United States, Bulgaria, Israel and more
  9. Jul 14, 2013Phase 2 study in Uveitis, PosteriorNCT01905124 · Israel
  10. Dec 16, 2015Phase 3 study in Arthritis, RheumatoidNCT02647762 · 244 enrolled · Bosnia and Herzegovina, Canada, Israel and more
  11. May 24, 2017Phase 3 study in Plaque PsoriasisNCT03168256 · 528 enrolled · Bosnia and Herzegovina, Bulgaria, Canada and more
  12. Apr 1, 2020Phase 2 study in COVID-19NCT04333472 · 6 enrolled · Bulgaria, Israel, Romania
  13. Oct 9, 2024Phase 3 study in PsoriasisNCT06643260 · 705 planned
  14. Feb 8, 2026Phase 2 study in Oculocerebrorenal SyndromeNCT07410455 · 5 planned · Italy

Ahead

  1. Aug 31, 2027Primary completion: phase 2 study in Oculocerebrorenal SyndromeNCT07410455
  2. Dec 2027Primary completion: phase 3 study in PsoriasisNCT06643260

TargetBeta

ADORA3 →read by rule
“An orally bioavailable, adenosine A3 receptor (A3AR) agonist ”NCIt, by rule
“Adenosine A3 receptor agonist”ChEMBL 37, by rule

Other programs on ADORA3

ProgramCompanyFurthest phaseStudies
CaffeineruleBoehringer Ingelheimphase 430

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07410455Oculocerebrorenal Syndrome · Italy2Not yet recruitingAug 31, 20275
NCT06643260Psoriasis3Not yet recruitingDec 2027705
NCT04333472COVID-19 · Bulgaria, Israel, Romania2CompletedMar 6, 20226
NCT03168256Plaque Psoriasis · Bosnia and Herzegovina, Bulgaria, Canada and more3CompletedJan 6, 2022528
NCT02647762Arthritis, Rheumatoid · Bosnia and Herzegovina, Canada, Israel and more3TerminatedNov 30, 2020244
NCT01905124Uveitis, Posterior · Israel2WithdrawnSep 20190
NCT01265667Psoriasis · United States, Bulgaria, Israel and more3CompletedMar 2015293
NCT01235234Keratoconjunctivitis Sicca · Israel3CompletedNov 2013236
NCT01034306Arthritis, Rheumatoid · Bulgaria, Israel2CompletedDec 201379
NCT01033422Ocular Hypertension · Bulgaria, Israel2CompletedDec 201689
NCT00837291Osteoarthritis, Knee · Israel2WithdrawnDec 20180
NCT00556894Arthritis, Rheumatoid · Bulgaria, Czechia, Israel and more2CompletedMar 2009253
NCT00428974Psoriasis · Israel2CompletedSep 200976
NCT00349466Keratoconjunctivitis Sicca · Israel2CompletedMay 200980
NCT00280917Arthritis, Rheumatoid · United States, Bulgaria, Israel and more2CompletedApr 2007254

How it is read

Names in the registry

  • “CF101”, 9 entries
  • “Piclidenoson”, 2 entries
  • “CF101 2mg”, 2 entries
  • “piclidenoson”, 1 entry
  • “CF101 1mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.